Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study

Monday, August 24, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences has initiated dosing in its Phase 1/2 FUNCTION-DMD clinical trial, focusing on PBGENE-DMD for Duchenne muscular dystrophy. This program aims to address a significant unmet medical need in the treatment of DMD. The trial marks a critical step in evaluating the efficacy of their gene editing therapy.

Market Sentiment Analysis

POSITIVE FACTORS

  • First patient dosed in the FUNCTION-DMD trial.
  • PBGENE-DMD targets a high unmet need in DMD treatment.
  • Utilizes Precision's innovative ARCUS platform.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the dosing of the first patient in August in the Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD). PBGENE-DMD is Precision's wholly owned in vivo gene editing program designed to durab

Frequently Asked Questions

What is the FUNCTION-DMD study?

The FUNCTION-DMD study is a Phase 1/2 clinical trial evaluating PBGENE-DMD for treating Duchenne muscular dystrophy.

What company is conducting the FUNCTION-DMD trial?

The trial is being conducted by Precision BioSciences, Inc.

What is PBGENE-DMD?

PBGENE-DMD is Precision's in vivo gene editing program aimed at treating Duchenne muscular dystrophy.

When was the first patient dosed in the trial?

The first patient was dosed in August.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences Duchenne muscular dystrophy PBGENE-DMD gene editing
Last updated: Aug 24, 2026

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →